Datapoint: CMS Finalizes Aduhelm Coverage Decision

CMS on April 7 finalized its narrow coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, limiting coverage to Medicare beneficiaries enrolled in clinical trials. The monoclonal antibody is the only drug approved to treat Alzheimer’s, and holds covered or better status for just 24% of all insured lives in the U.S.

SOURCE: MMIT Analytics, as of 4/12/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today